Evidence map›Paper›PMID 40750838›Full record

ArticleBMC bioinformatics2025

Literature data-based de novo candidates for drug repurposing.

Xianglong Liang, Xin Jiang, Yifang Ma

Abstract read
In one paragraph

Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xianglong LiangDepartment of Statistics and Data Science, Southern University of Science and Technology, Shenzhen, China.
Xin JiangInstitute of Artificial Intelligence & Beijing Advanced Innovation Center for Future Blockchain and Privacy Computing & LMIB, Beihang University, Beijing, China.
Yifang MaDepartment of Statistics and Data Science, Southern University of Science and Technology, Shenzhen, China. mayf@sustech.edu.cn.

Funding

National Natural Science Foundation of China No. 62006109Stable Support Plan Program of Shenzhen Natural Science Fund 20220814165010001
6 · The paper itself

Abstract

backgroundDrug repurposing offers a promising strategy for drug discovery. Drug repurposing involves identifying new therapeutic indications for existing, marketed drugs, thereby reducing the risks, costs, and time typically required for drug development. Various methods exist for drug repurposing, including high-throughput screening of drug compound libraries, computation in silico approaches, literature-based methods, etc. Currently, numerous methods utilize literature for data mining in drug repositioning; however, relatively few approaches leverage literature citation networks for this purpose.

resultsWe identified 19,553 potential drug pairs for repurposing by analyzing biomedical literature data through the Jaccard coefficient. Our results demonstrated that the literature-based Jaccard coefficient was the most effective similarity metric for identifying drug repurposing opportunities. To refine our selection process, we applied a threshold defined by the upper γth quantile value of the Jaccard coefficient, enabling us to prioritize promising de novo drug repurposing candidates. Among the identified drug pairs, we found several with strong potential for repurposing, including combinations such as adapalene and bexarotene, guanabenz and tizanidine, alvimopan and methylnaltrexone, etc.

conclusionWe created a validation set consisting of both true positives and true negatives for drug pairs using the repoDB dataset, a widely recognized resource for drug repurposing. To evaluate the performance of various similarity metrics for drug pairs, we compared their effectiveness based on AUC, F1 score, and AUCPR using the validation set.

Indexed as

Data MiningDrug RepositioningDrug DiscoveryCandidate repurposing drug pairsDrug repurposingLiterature citation networkNetwork analysisValidation the results

Identifiers

PMID40750838
PMCPMC12317455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.